-
Je něco špatně v tomto záznamu ?
Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma
P. Stejskal, M. Vaverka, S. Trnka, M. Hampl, L. Hrabalek
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
32686773
DOI
10.5507/bp.2020.029
Knihovny.cz E-zdroje
- MeSH
- chronický subdurální hematom * farmakoterapie etiologie MeSH
- drenáž MeSH
- inhibitory ACE škodlivé účinky MeSH
- lidé MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. PATIENTS AND METHODS: The study recruited patients treated surgically for CSDH at our department in the 2013-2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological - the use of ACEI) and the course of treatment focussing on the reoccurrence of disease necessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. RESULTS: Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. CONCLUSION: The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publication of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22007870
- 003
- CZ-PrNML
- 005
- 20220330125804.0
- 007
- ta
- 008
- 220309s2021 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2020.029 $2 doi
- 035 __
- $a (PubMed)32686773
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Stejskal, Přemysl $7 xx0234320 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
- 245 10
- $a Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma / $c P. Stejskal, M. Vaverka, S. Trnka, M. Hampl, L. Hrabalek
- 504 __
- $a Literatura
- 520 9_
- $a AIMS: Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. PATIENTS AND METHODS: The study recruited patients treated surgically for CSDH at our department in the 2013-2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological - the use of ACEI) and the course of treatment focussing on the reoccurrence of disease necessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. RESULTS: Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. CONCLUSION: The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publication of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.
- 650 _2
- $a inhibitory ACE $x škodlivé účinky $7 D000806
- 650 _2
- $a drenáž $7 D004322
- 650 12
- $a chronický subdurální hematom $x farmakoterapie $x etiologie $7 D020200
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vaverka, Miroslav, $d 1952- $7 skuk0005716 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Trnka, Štefan $7 xx0240181 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Hampl, Martin $7 xx0234317 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Hrabálek, Lumír $7 xx0076898 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 2 (2021), s. 175-178
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32686773 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20220309 $b ABA008
- 991 __
- $a 20220330125759 $b ABA008
- 999 __
- $a ok $b bmc $g 1775507 $s 1159063
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 165 $c 2 $d 175-178 $e 20200716 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20220309